NASDAQ:CORT

Corcept Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CORT

*Your capital is at risk

$114.49

-3.83 (-3.24%)

At Close: Jul 31, 2026

Corcept Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -71.45. In total, the insiders bought 1.13M and sold 1.75M CORT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-71.45
● Buy	1.13M shares
● Sell	1.75M shares
51% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence May 27, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -71.45. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 15, 2026 Sell	Common Stock S-Sale	Wilson James N Director	Director	3 969 Value: $348.2K
Jul 15, 2026 Sell	Common Stock S-Sale	Wilson James N Director	Director	1 079 Value: $93.6K
Jul 15, 2026 Sell	Common Stock S-Sale	Wilson James N Director	Director	2 974 Value: $264.1K
Jul 15, 2026 Buy	Stock option (right to buy) M-Exempt	Mokari Atabak Chief Financial Officer	C-Suite Officer	15 833 Value: $304.9K
Jul 15, 2026 Sell	Common Stock S-Sale	Mokari Atabak Chief Financial Officer	C-Suite Officer	101 Value: $9K
Jul 15, 2026 Sell	Common Stock S-Sale	Mokari Atabak Chief Financial Officer	C-Suite Officer	3 520 Value: $310.8K
Jul 15, 2026 Buy	Common Stock M-Exempt	Mokari Atabak Chief Financial Officer	C-Suite Officer	24 167 Value: $557.3K
Jul 15, 2026 Buy	Stock option (right to buy) M-Exempt	Mokari Atabak Chief Financial Officer	C-Suite Officer	24 167 Value: $557.3K
Jul 15, 2026 Sell	Common Stock S-Sale	Wilson James N Director	Director	1 978 Value: $177.0K
Jul 15, 2026 Sell	Common Stock S-Sale	Mokari Atabak Chief Financial Officer	C-Suite Officer	28 460 Value: $2.50M
Jul 15, 2026 Buy	Common Stock M-Exempt	Mokari Atabak Chief Financial Officer	C-Suite Officer	15 833 Value: $304.9K
Jul 15, 2026 Sell	Common Stock S-Sale	Mokari Atabak Chief Financial Officer	C-Suite Officer	7 919 Value: $687.2K
Jul 07, 2026 Buy	Stock Option (right to buy) M-Exempt	Guyer William Chief Development Officer	Officer	20 000 Value: $433.0K
Jul 07, 2026 Buy	Common Stock M-Exempt	Guyer William Chief Development Officer	Officer	20 000 Value: $433.0K
Jul 07, 2026 Sell	Common Stock S-Sale	Guyer William Chief Development Officer	Officer	19 048 Value: $1.77M
Jul 07, 2026 Sell	Common Stock S-Sale	Guyer William Chief Development Officer	Officer	952 Value: $89.0K
Jul 01, 2026 Sell	Common Stock S-Sale	Maduck Sean See Remarks	Officer	11 024 Value: $962.8K
Jul 01, 2026 Sell	Common Stock S-Sale	Maduck Sean See Remarks	Officer	2 801 Value: $247.9K
Jul 01, 2026 Sell	Common Stock S-Sale	Maduck Sean See Remarks	Officer	11 175 Value: $998.0K
Jul 01, 2026 Buy	Stock option (right to buy) M-Exempt	Maduck Sean See Remarks	Officer	25 000 Value: $206.8K
Jul 01, 2026 Buy	Common Stock M-Exempt	Maduck Sean See Remarks	Officer	25 000 Value: $206.8K
Jun 17, 2026 Sell	Common Stock S-Sale	Mahoney David L Director	Director	20 000 Value: $1.69M
Jun 16, 2026 Sell	Common Stock S-Sale	Wilson James N Director	Director	4 177 Value: $345.4K
Jun 16, 2026 Sell	Common Stock S-Sale	Wilson James N Director	Director	5 823 Value: $486.6K
Jun 15, 2026 Sell	Common Stock S-Sale	Mokari Atabak Chief Financial Officer	C-Suite Officer	11 081 Value: $896.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CORCEPT THERAPEUTICS INCORPORATED

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have ...

Read Full Profile Here